Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206390
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 2,191 | 1,208 |
| Operating lease right-of-use assets | 105 | 112 |
| Depreciation and amortization | 34 | 37 |
| Accretion of available-for-sale marketable securities, net | (431) | (395) |
| Changes in operating assets and liabilities: | ||
| Accrued expenses and other liabilities | (1,075) | (1,501) |
| Accounts payable | (1,483) | (1,993) |
Item 1. Condensed Consolidated Financial Statements.
FAQ
- What is Trevi Therapeutics, Inc.'s D&A?
- Trevi Therapeutics, Inc. (TRVI) reported D&A of $34K in Q1 2026.
- How has Trevi Therapeutics, Inc.'s D&A changed year-over-year?
- Trevi Therapeutics, Inc.'s D&A decreased by 8.1% year-over-year, from $37K to $34K.
- What is the long-term trend for Trevi Therapeutics, Inc.'s D&A?
- Over 3 years (2022 to 2025), Trevi Therapeutics, Inc.'s D&A has grown at a 49.6% compound annual growth rate (CAGR), from $43K to $144K.
- What does D&A mean?
- Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.
Ask your AI about Trevi Therapeutics, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude